Published in N Engl J Med on February 18, 1999
Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerg Infect Dis (2007) 6.75
Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc Natl Acad Sci U S A (2007) 6.14
Antimicrobial resistance: the example of Staphylococcus aureus. J Clin Invest (2003) 5.33
Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with l-lysine. J Exp Med (2001) 5.06
Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Antimicrob Agents Chemother (2002) 4.83
Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev (2010) 4.76
Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis (2001) 4.19
Development of a Canadian standardized protocol for subtyping methicillin-resistant Staphylococcus aureus using pulsed-field gel electrophoresis. J Clin Microbiol (2001) 4.05
Purification and characterization of sortase, the transpeptidase that cleaves surface proteins of Staphylococcus aureus at the LPXTG motif. Proc Natl Acad Sci U S A (1999) 3.90
Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J Clin Microbiol (2003) 3.89
Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania. Antimicrob Agents Chemother (2004) 3.44
An iron-regulated sortase anchors a class of surface protein during Staphylococcus aureus pathogenesis. Proc Natl Acad Sci U S A (2002) 3.23
Chemotaxis inhibitory protein of Staphylococcus aureus, a bacterial antiinflammatory agent. J Exp Med (2004) 2.96
Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob Agents Chemother (2003) 2.80
Evolution of a vancomycin-intermediate Staphylococcus aureus strain in vivo: multiple changes in the antibiotic resistance phenotypes of a single lineage of methicillin-resistant S. aureus under the impact of antibiotics administered for chemotherapy. J Clin Microbiol (2003) 2.74
A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides. J Clin Microbiol (2006) 2.74
The D-alanine residues of Staphylococcus aureus teichoic acids alter the susceptibility to vancomycin and the activity of autolytic enzymes. Antimicrob Agents Chemother (2000) 2.71
Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother (2006) 2.51
Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates. Antimicrob Agents Chemother (2000) 2.48
Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother (2006) 2.43
Overexpression of genes of the cell wall stimulon in clinical isolates of Staphylococcus aureus exhibiting vancomycin-intermediate- S. aureus-type resistance to vancomycin. J Bacteriol (2006) 2.32
Characterization of passage-selected vancomycin-resistant Staphylococcus aureus strains of diverse parental backgrounds. Antimicrob Agents Chemother (2000) 2.32
Molecular detection of antimicrobial resistance. Clin Microbiol Rev (2001) 2.31
Alterations of cell wall structure and metabolism accompany reduced susceptibility to vancomycin in an isogenic series of clinical isolates of Staphylococcus aureus. J Bacteriol (2003) 2.21
Vancomycin-intermediate Staphylococcus aureus in Korea. J Clin Microbiol (2000) 2.16
Reduced content of lysyl-phosphatidylglycerol in the cytoplasmic membrane affects susceptibility to moenomycin, as well as vancomycin, gentamicin, and antimicrobial peptides, in Staphylococcus aureus. Antimicrob Agents Chemother (2004) 2.15
Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR. PLoS Pathog (2011) 2.15
Structure of sortase, the transpeptidase that anchors proteins to the cell wall of Staphylococcus aureus. Proc Natl Acad Sci U S A (2001) 2.03
Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the "seesaw effect"). Antimicrob Agents Chemother (2010) 1.98
Heterogeneous vancomycin resistance in methicillin-resistant Staphylococcus aureus strains isolated in a large Italian hospital. J Clin Microbiol (2000) 1.98
International clones of methicillin-resistant Staphylococcus aureus in two hospitals in Miami, Florida. J Clin Microbiol (2004) 1.94
Staphylococcus aureus susceptibility to innate antimicrobial peptides, beta-defensins and CAP18, expressed by human keratinocytes. Infect Immun (2003) 1.90
BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis. Antimicrob Agents Chemother (2002) 1.88
Three-year assessment of methicillin-resistant Staphylococcus aureus clones in Latin America from 1996 to 1998. J Clin Microbiol (2001) 1.88
Dissemination of methicillin-resistant Staphylococcus aureus USA300 sequence type 8 lineage in Latin America. Clin Infect Dis (2009) 1.77
A spectrum of changes occurs in peptidoglycan composition of glycopeptide-intermediate clinical Staphylococcus aureus isolates. Antimicrob Agents Chemother (2001) 1.73
Quinolones: action and resistance updated. Curr Top Med Chem (2009) 1.73
First report of methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Thailand. J Clin Microbiol (2001) 1.69
Morphological and genetic differences in two isogenic Staphylococcus aureus strains with decreased susceptibilities to vancomycin. Antimicrob Agents Chemother (2003) 1.67
tcaA inactivation increases glycopeptide resistance in Staphylococcus aureus. Antimicrob Agents Chemother (2004) 1.64
Inducible azole resistance associated with a heterogeneous phenotype in Candida albicans. Antimicrob Agents Chemother (2001) 1.58
Katanosin B and plusbacin A(3), inhibitors of peptidoglycan synthesis in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (2001) 1.57
Real-time in vivo bioluminescent imaging for evaluating the efficacy of antibiotics in a rat Staphylococcus aureus endocarditis model. Antimicrob Agents Chemother (2005) 1.54
Emergence in Asian countries of Staphylococcus aureus with reduced susceptibility to vancomycin. Antimicrob Agents Chemother (2004) 1.48
Genetic pathway in acquisition and loss of vancomycin resistance in a methicillin resistant Staphylococcus aureus (MRSA) strain of clonal type USA300. PLoS Pathog (2012) 1.44
Clonal spread of Staphylococcus aureus heterogeneously resistant to vancomycin in a university hospital in Korea. J Clin Microbiol (2002) 1.37
Dialysis-associated peritonitis in children. Pediatr Nephrol (2009) 1.35
Outbreak of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in a Parisian hospital. J Clin Microbiol (2000) 1.33
New resistance in Staphylococcus aureus. N Engl J Med (1999) 1.30
Molecular epidemiology of Staphylococcus epidermidis in a neonatal intensive care unit over a three-year period. J Clin Microbiol (2000) 1.28
walK and clpP mutations confer reduced vancomycin susceptibility in Staphylococcus aureus. Antimicrob Agents Chemother (2011) 1.27
A mecA-negative strain of methicillin-resistant Staphylococcus aureus with high-level β-lactam resistance contains mutations in three genes. Antimicrob Agents Chemother (2010) 1.26
Combination effect of vancomycin and beta-lactams against a Staphylococcus aureus strain, Mu3, with heterogeneous resistance to vancomycin. Antimicrob Agents Chemother (2001) 1.18
Hetero-vancomycin-intermediate methicillin-resistant Staphylococcus aureus isolate from a medical center in Las Cruces, New Mexico. J Clin Microbiol (2007) 1.17
Modulation of fibronectin adhesins and other virulence factors in a teicoplanin-resistant derivative of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (2004) 1.16
Low-level vancomycin resistance in Staphylococcus aureus--an Australian perspective. Eur J Clin Microbiol Infect Dis (2005) 1.16
Mechanisms of vancomycin resistance in Staphylococcus aureus. J Clin Invest (2014) 1.15
Nationwide surveillance for Staphylococcus aureus with reduced susceptibility to vancomycin in Korea. J Clin Microbiol (2003) 1.15
Fluorescence ratio imaging microscopy shows decreased access of vancomycin to cell wall synthetic sites in vancomycin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (2007) 1.14
Purification, characterization, and identification of novel inhibitors of the beta-ketoacyl-acyl carrier protein synthase III (FabH) from Staphylococcus aureus. Antimicrob Agents Chemother (2002) 1.14
In vitro synergistic effects of double and triple combinations of beta-lactams, vancomycin, and netilmicin against methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother (2000) 1.13
Clinical implications of varying degrees of vancomycin susceptibility in methicillin-resistant Staphylococcus aureus bacteremia. Emerg Infect Dis (2003) 1.13
Transcriptomic and functional analysis of an autolysis-deficient, teicoplanin-resistant derivative of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (2006) 1.12
Increased glycan chain length distribution and decreased susceptibility to moenomycin in a vancomycin-resistant Staphylococcus aureus mutant. Antimicrob Agents Chemother (2002) 1.10
Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem. Antimicrob Agents Chemother (2009) 1.09
Safety and immunogenicity of a novel Staphylococcus aureus vaccine: results from the first study of the vaccine dose range in humans. Clin Vaccine Immunol (2010) 1.07
Resistance to autolysis in vancomycin-selected Staphylococcus aureus isolates precedes vancomycin-intermediate resistance. Antimicrob Agents Chemother (2003) 1.04
Clonal groups of penicillin-nonsusceptible Streptococcus pneumoniae in Baltimore, Maryland: a population-based, molecular epidemiologic study. J Clin Microbiol (2000) 1.04
Prevalence, molecular epidemiology, and clinical significance of heterogeneous glycopeptide-intermediate Staphylococcus aureus in liver transplant recipients. J Clin Microbiol (2003) 1.04
7-O-malonyl macrolactin A, a new macrolactin antibiotic from Bacillus subtilis active against methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, and a small-colony variant of Burkholderia cepacia. Antimicrob Agents Chemother (2006) 1.04
The effects of vancomycin and beta-lactam antibiotics on vancomycin-resistant Staphylococcus aureus. N Engl J Med (1999) 1.03
Optimizing antibiotic therapy in the intensive care unit setting. Crit Care (2001) 1.02
Vancomycin and oxacillin synergy for methicillin-resistant staphylococci. Antimicrob Agents Chemother (2000) 1.01
Pharmacokinetic-pharmacodynamic relationship of arbekacin for treatment of patients infected with methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (2006) 1.00
Survey of methicillin-resistant Staphylococcus aureus strains from two hospitals in El Paso, Texas. J Clin Microbiol (2005) 1.00
Nationwide survey shows that methicillin-resistant Staphylococcus aureus strains heterogeneously and intermediately resistant to vancomycin are not disseminated throughout Japanese hospitals. J Clin Microbiol (2001) 0.99
Staphylococcus aureus isolates with reduced susceptibility to glycopeptides belong to accessory gene regulator group I or II. Antimicrob Agents Chemother (2004) 0.98
Current and novel antibiotics against resistant Gram-positive bacteria. Infect Drug Resist (2008) 0.98
Unstable vancomycin heteroresistance is common among clinical isolates of methiciliin-resistant Staphylococcus aureus. J Clin Microbiol (2005) 0.97
Fluoroquinolone and quinazolinedione activities against wild-type and gyrase mutant strains of Mycobacterium smegmatis. Antimicrob Agents Chemother (2011) 0.97
Comparative study of the susceptibilities of major epidemic clones of methicillin-resistant Staphylococcus aureus to oxacillin and to the new broad-spectrum cephalosporin ceftobiprole. Antimicrob Agents Chemother (2008) 0.97
Glycopeptide resistance in coagulase-negative staphylococci isolated in blood cultures from patients with hematological malignancies during three decades. Eur J Clin Microbiol Infect Dis (2011) 0.97
Autolytic properties of glycopeptide-intermediate Staphylococcus aureus Mu50. Antimicrob Agents Chemother (2006) 0.96
Comprehensive identification of mutations responsible for heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA)-to-VISA conversion in laboratory-generated VISA strains derived from hVISA clinical strain Mu3. Antimicrob Agents Chemother (2013) 0.94
Vancomycin penetration of uninfected pleural fluid exudate after continuous or intermittent infusion. Antimicrob Agents Chemother (2003) 0.93
Immunological control of methicillin-resistant Staphylococcus aureus (MRSA) infection in an immunodeficient murine model of thermal injuries. Clin Exp Immunol (2005) 0.93
Glycopeptide susceptibility profiles of Staphylococcus haemolyticus bloodstream isolates. Antimicrob Agents Chemother (2000) 0.93
Bench-to-bedside review: antimicrobial utilization strategies aimed at preventing the emergence of bacterial resistance in the intensive care unit. Crit Care (2005) 0.93
Novel approach for comparing the abilities of quinolones to restrict the emergence of resistant mutants during quinolone exposure. Antimicrob Agents Chemother (2009) 0.92
Dalbavancin in the treatment of complicated skin and soft-tissue infections: a review. Ther Clin Risk Manag (2008) 0.92
Methicillin-resistant, quinupristin-dalfopristin-resistant Staphylococcus aureus with reduced sensitivity to glycopeptides. J Clin Microbiol (2001) 0.91
Clinical failure of vancomycin in a dialysis patient with methicillin-susceptible vancomycin-heteroresistant S. aureus. Diagn Microbiol Infect Dis (2009) 0.91
Enhancement of neutrophil function by interleukin-18 therapy protects burn-injured mice from methicillin-resistant Staphylococcus aureus. Infect Immun (2011) 0.90
Failure of vancomycin continuous infusion against experimental endocarditis due to vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother (2010) 0.88
Observation of "seesaw effect" with vancomycin, teicoplanin, daptomycin and ceftaroline in 150 unique MRSA strains. Infect Dis Ther (2014) 0.86
Genomic diversification of enterococci in hosts: the role of the mobilome. Front Microbiol (2012) 0.86
Decoupling competing surface binding kinetics and reconfiguration of receptor footprint for ultrasensitive stress assays. Nat Nanotechnol (2015) 0.85
Staphylococcus heterogeneously resistant to vancomycin in China and antimicrobial activities of imipenem and vancomycin in combination against it. J Clin Microbiol (2002) 0.85
Trends in hospitalizations with antibiotic-resistant infections: U.S., 1997-2006. Public Health Rep (2011) 0.85
VISA, hetero-VISA and VRSA: the end of the vancomycin era? Can J Infect Dis (2002) 0.84
Low-affinity penicillin-binding protein associated with beta-lactam resistance in Staphylococcus aureus. J Bacteriol (1984) 14.64
High-Resolution Density Gradient Sedimentation Analysis. Science (1960) 12.12
Multiple antibiotic resistance in a bacterium with suppressed autolytic system. Nature (1970) 9.07
SYNTHESIS OF NASCENT PROTEIN BY RIBOSOMES IN ESCHERICHIA COLI. Proc Natl Acad Sci U S A (1959) 8.76
The evolution of pandemic clones of methicillin-resistant Staphylococcus aureus: identification of two ancestral genetic backgrounds and the associated mec elements. Microb Drug Resist (2001) 7.78
Expression of methicillin resistance in heterogeneous strains of Staphylococcus aureus. Antimicrob Agents Chemother (1986) 7.71
Penicillin-binding proteins of multiply antibiotic-resistant South African strains of Streptococcus pneumoniae. Antimicrob Agents Chemother (1980) 6.96
Nomenclature of major antimicrobial-resistant clones of Streptococcus pneumoniae defined by the pneumococcal molecular epidemiology network. J Clin Microbiol (2001) 6.66
AMINO ACID ADSORPTION AND PROTEIN SYNTHESIS IN Escherichia Coli. Proc Natl Acad Sci U S A (1955) 6.29
Choline-containing teichoic acid as a structural component of pneumococcal cell wall and its role in sensitivity to lysis by an autolytic enzyme. J Biol Chem (1970) 6.06
Biological consequences of the replacement of choline by ethanolamine in the cell wall of Pneumococcus: chanin formation, loss of transformability, and loss of autolysis. Proc Natl Acad Sci U S A (1968) 5.92
Horizontal transfer of penicillin-binding protein genes in penicillin-resistant clinical isolates of Streptococcus pneumoniae. Proc Natl Acad Sci U S A (1989) 5.65
On the nature of the pneumococcal activator substance. Proc Natl Acad Sci U S A (1966) 5.54
Choline in the cell wall of a bacterium: novel type of polymer-linked choline in Pneumococcus. Science (1967) 5.51
The evolution of methicillin resistance in Staphylococcus aureus: similarity of genetic backgrounds in historically early methicillin-susceptible and -resistant isolates and contemporary epidemic clones. Proc Natl Acad Sci U S A (2001) 5.45
The mechanism of the irreversible antimicrobial effects of penicillins: how the beta-lactam antibiotics kill and lyse bacteria. Annu Rev Microbiol (1979) 5.33
Multiple changes of penicillin-binding proteins in penicillin-resistant clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother (1980) 5.12
Cellular metabolism in genetic transformation of pneumococci: requirement for protein synthesis during induction of competence. J Bacteriol (1970) 4.99
Peptidoglycan composition of a highly methicillin-resistant Staphylococcus aureus strain. The role of penicillin binding protein 2A. J Biol Chem (1992) 4.92
Involvement of multiple genetic determinants in high-level methicillin resistance in Staphylococcus aureus. J Bacteriol (1989) 4.91
Mechanism of action of penicillin: triggering of the pneumococcal autolytic enzyme by inhibitors of cell wall synthesis. Proc Natl Acad Sci U S A (1975) 4.85
Penicillin-binding proteins of penicillin-susceptible and intrinsically resistant Neisseria gonorrhoeae. Antimicrob Agents Chemother (1980) 4.80
Spread and maintenance of a dominant methicillin-resistant Staphylococcus aureus (MRSA) clone during an outbreak of MRSA disease in a Spanish hospital. J Clin Microbiol (1994) 4.68
Campylobacteriosis in man: pathogenic mechanisms and review of 91 bloodstream infections. Am J Med (1978) 4.56
Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus. J Bacteriol (1997) 4.52
Molecular typing of methicillin-resistant Staphylococcus aureus by pulsed-field gel electrophoresis: comparison of results obtained in a multilaboratory effort using identical protocols and MRSA strains. Microb Drug Resist (2000) 4.24
Multiple mechanisms of methicillin resistance and improved methods for detection in clinical isolates of Staphylococcus aureus. Antimicrob Agents Chemother (1991) 4.22
The rate of killing of Escherichia coli by beta-lactam antibiotics is strictly proportional to the rate of bacterial growth. J Gen Microbiol (1986) 4.09
Molecular epidemiology of methicillin-resistant Staphylococcus aureus in 12 New York hospitals. MRSA Collaborative Study Group. J Infect Dis (1998) 3.94
Evidence for the introduction of a multiresistant clone of serotype 6B Streptococcus pneumoniae from Spain to Iceland in the late 1980s. J Infect Dis (1993) 3.94
Methicillin-resistant Staphylococcus aureus disease in a Portuguese hospital: characterization of clonal types by a combination of DNA typing methods. Eur J Clin Microbiol Infect Dis (1994) 3.87
CD14 is a pattern recognition receptor. Immunity (1994) 3.79
Model for the mechanism controlling the expression of competent state in Pneumococcus cultures. J Bacteriol (1966) 3.77
Lipoteichoic acid: a specific inhibitor of autolysin activity in Pneumococcus. Proc Natl Acad Sci U S A (1975) 3.76
Impaired production of lymphokines and immune (gamma) interferon in the acquired immunodeficiency syndrome. N Engl J Med (1984) 3.73
Viridans streptococcal endocarditis: the role of various species, including pyridoxal-dependent streptococci. Rev Infect Dis (1980) 3.70
The induction of meningeal inflammation by components of the pneumococcal cell wall. J Infect Dis (1985) 3.66
Sigma-B, a putative operon encoding alternate sigma factor of Staphylococcus aureus RNA polymerase: molecular cloning and DNA sequencing. J Bacteriol (1996) 3.58
Geographic distribution of penicillin-resistant clones of Streptococcus pneumoniae: characterization by penicillin-binding protein profile, surface protein A typing, and multilocus enzyme analysis. Clin Infect Dis (1992) 3.52
Reassessment of the number of auxiliary genes essential for expression of high-level methicillin resistance in Staphylococcus aureus. Antimicrob Agents Chemother (1994) 3.50
Evidence for the geographic spread of a methicillin-resistant Staphylococcus aureus clone between Portugal and Spain. J Clin Microbiol (1995) 3.45
Conversion of a homogeneously methicillin-resistant strain of Staphylococcus aureus to heterogeneous resistance by Tn551-mediated insertional inactivation. Eur J Clin Microbiol (1986) 3.44
Increased amounts of a novel penicillin-binding protein in a strain of methicillin-resistant Staphylococcus aureus exposed to nafcillin. J Clin Invest (1985) 3.35
Pneumococcal Forssman antigen. A choline-containing lipoteichoic acid. J Biol Chem (1973) 3.31
Altered penicillin-binding proteins in methicillin-resistant strains of Staphylococcus aureus. Antimicrob Agents Chemother (1981) 3.29
Geographic spread of epidemic multiresistant Staphylococcus aureus clone in Brazil. J Clin Microbiol (1995) 3.24
Extremely high incidence of antibiotic resistance in clinical isolates of Streptococcus pneumoniae in Hungary. J Infect Dis (1991) 3.18
Tolerant response of Streptococcus sanguis to beta-lactams and other cell wall inhibitors. Antimicrob Agents Chemother (1977) 3.17
The Synthesis of Ribosomes in E. coli: III. Synthesis of Ribosomal RNA. Biophys J (1962) 3.14
A Staphylococcus aureus autolysin that has an N-acetylmuramoyl-L-alanine amidase domain and an endo-beta-N-acetylglucosaminidase domain: cloning, sequence analysis, and characterization. Proc Natl Acad Sci U S A (1995) 3.12
Insertional inactivation of the mec gene in a transposon mutant of a methicillin-resistant clinical isolate of Staphylococcus aureus. Antimicrob Agents Chemother (1990) 3.09
The protean manifestations of Mycoplasma pneumoniae infection in adults. Am J Med (1975) 3.06
Inhibition of bacterial wall lysins by lipoteichoic acids and related compounds. Biochem Biophys Res Commun (1975) 3.01
The role of autolysins in cell death. Ann N Y Acad Sci (1974) 2.99
The relationship between group A and group C meningococcal polysaccharides and serum opsonins in man. J Exp Med (1970) 2.97
Isolation and characterization of a Tn551-autolysis mutant of Staphylococcus aureus. J Bacteriol (1992) 2.92
Gram-positive cell walls stimulate synthesis of tumor necrosis factor alpha and interleukin-6 by human monocytes. Infect Immun (1994) 2.92
The interaction in vitro between group B meningococci and rabbit polymorphonuclear leukocytes. Demonstration of type specific opsonins and bactericidins. J Exp Med (1967) 2.89
Inactivated pbp4 in highly glycopeptide-resistant laboratory mutants of Staphylococcus aureus. J Biol Chem (1999) 2.89
An acquired and a native penicillin-binding protein cooperate in building the cell wall of drug-resistant staphylococci. Proc Natl Acad Sci U S A (2001) 2.85
Control of the competent state in Pneumococcus by a hormone-like cell product: an example for a new type of regulatory mechanism in bacteria. Nature (1965) 2.84
Alteration of Escherichia coli murein during amino acid starvation. J Bacteriol (1980) 2.78
Evolution of a vancomycin-intermediate Staphylococcus aureus strain in vivo: multiple changes in the antibiotic resistance phenotypes of a single lineage of methicillin-resistant S. aureus under the impact of antibiotics administered for chemotherapy. J Clin Microbiol (2003) 2.74
Penicillin-binding proteins of penicillin-susceptible and -resistant pneumococci: immunological relatedness of altered proteins and changes in peptides carrying the beta-lactam binding site. Antimicrob Agents Chemother (1986) 2.72
Evaluation of the bactericidal activity of beta-lactam antibiotics on slowly growing bacteria cultured in the chemostat. Antimicrob Agents Chemother (1986) 2.68
Molecular characterization of penicillin-resistant Streptococcus pneumoniae isolates causing respiratory disease in the United States. Microb Drug Resist (1998) 2.62
Frequent recovery of a single clonal type of multidrug-resistant Staphylococcus aureus from patients in two hospitals in Taiwan and China. J Clin Microbiol (2003) 2.55
Streptococcus bovis bacteremia and underlying gastrointestinal disease. Arch Intern Med (1978) 2.54
Purification of the pneumococcal N-acetylmuramyl-L-alanine amidase to biochemical homogeneity. J Biol Chem (1976) 2.52
Abnormal autolytic enzyme in a pneumococus with altered teichoic acid composition. Proc Natl Acad Sci U S A (1971) 2.51
Specific recognition of choline residues in the cell wall teichoic acid by the N-acetylmuramyl-L-alanine amidase of Pneumococcus. J Biol Chem (1975) 2.50
Serious infections caused by Streptococcus milleri. Am J Med (1978) 2.47
Structure of the peptide network of pneumococcal peptidoglycan. J Biol Chem (1987) 2.45
Tracking the evolutionary origin of the methicillin resistance gene: cloning and sequencing of a homologue of mecA from a methicillin susceptible strain of Staphylococcus sciuri. Microb Drug Resist (1996) 2.43
Suppression of autolysis and cell wall turnover in heterogeneous Tn551 mutants of a methicillin-resistant Staphylococcus aureus strain. J Bacteriol (1991) 2.42
Beta-lactam-specific resistant mutants of Staphylococcus aureus. Antimicrob Agents Chemother (1986) 2.41
Activation of the alternative complement pathway by pneumococcal cell wall teichoic acid. J Immunol (1978) 2.40
Vitamin B6-dependent Streptococcus mitior (mitis) isolated from patients with systemic infections. J Infect Dis (1975) 2.37
An autoradiographic study of genetic transformation. Proc Natl Acad Sci U S A (1968) 2.36
Antibiotic resistance as a stress response: complete sequencing of a large number of chromosomal loci in Staphylococcus aureus strain COL that impact on the expression of resistance to methicillin. Microb Drug Resist (1999) 2.35
Specificity of DNA uptake in genetic transformation of gonococci. Biochem Biophys Res Commun (1979) 2.34
The relative role of bacterial cell wall and capsule in the induction of inflammation in pneumococcal meningitis. J Infect Dis (1985) 2.34
Capsular transformation of a multidrug-resistant Streptococcus pneumoniae in vivo. J Infect Dis (1998) 2.33
Antibiotic tolerance among clinical isolates of bacteria. Rev Infect Dis (1985) 2.32
Transmission of multidrug-resistant serotype 23F Streptococcus pneumoniae in group day care: evidence suggesting capsular transformation of the resistant strain in vivo. J Infect Dis (1995) 2.31
Secretion of lipids induced by inhibition of peptidoglycan synthesis in streptococci. J Bacteriol (1977) 2.31
From penicillin-binding proteins to the lysis and death of bacteria: a 1979 view. Rev Infect Dis (1980) 2.31
Severe measles pneumonitis in adults: evaluation of clinical characteristics and therapy with intravenous ribavirin. Clin Infect Dis (1994) 2.30
Gradual alterations in cell wall structure and metabolism in vancomycin-resistant mutants of Staphylococcus aureus. J Bacteriol (1999) 2.29
In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother (1980) 2.29
Triggering of autolytic cell wall degradation in Escherichia coli by beta-lactam antibiotics. Antimicrob Agents Chemother (1979) 2.26
Suppression of lytic effect of beta lactams on Escherichia coli and other bacteria. Proc Natl Acad Sci U S A (1976) 2.22
Alterations of cell wall structure and metabolism accompany reduced susceptibility to vancomycin in an isogenic series of clinical isolates of Staphylococcus aureus. J Bacteriol (2003) 2.21
The pgdA gene encodes for a peptidoglycan N-acetylglucosamine deacetylase in Streptococcus pneumoniae. J Biol Chem (2000) 2.19
A biological price of antibiotic resistance: major changes in the peptidoglycan structure of penicillin-resistant pneumococci. Proc Natl Acad Sci U S A (1990) 2.18
Penicillin-binding proteins and the antibacterial effectiveness of beta-lactam antibiotics. Rev Infect Dis (1986) 2.14
Variation in penicillin-binding protein patterns of penicillin-resistant clinical isolates of pneumococci. J Clin Microbiol (1989) 2.13
Studies on the mechanism of intrinsic resistance to beta-lactam antibiotics in group D streptococci. J Gen Microbiol (1983) 2.10